FTC Set To Take Enforcement Action Against Drugmakers Over Orange Book Patent Listings

 
• By Brenda Sandburg

Merger reviews could take into account sponsor's Orange Book behavior. FTC's statement does not detail what would make a patent listing 'improper' but the precedents from court cases against various sponsors should offer industry some guideposts.

Orange Book
FTC targets improper patent listings in FDA's Orange Book • Source: Shutterstock

More from Generics

More from Products